Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis

Keyphrases

• Randomized Trial 100%
• Risk-benefit 100%
• Clinical Risk 100%
• Risk-benefit Analysis 100%
• Thrombosis 60%
• Ximelagatran 60%
• Type of Surgery 40%
• Incremental Risk 20%
• Major Bleeding 20%
• Meta-analysis 20%
• Placebo 20%
• Warfarin 20%
• Case Fatality Rate 20%
• Bleeding 20%
• Anticoagulants 20%
• Clinical Decision-making 20%
• Rate Ratio 20%
• Risk-benefit Ratio 20%
• Orthopedic Surgery 20%
• Cost-effectiveness 20%
• Low Molecular Weight Heparin 20%
• Major Orthopedic Surgery 20%
• Unfractionated Heparin 20%
• Thromboprophylaxis 20%
• Monte Carlo Simulation 20%
• Net Clinical Benefit 20%
• Clinical Perspective 20%
• Personal Risk 20%
• Fondaparinux 20%
• Total Hip Replacement 20%
• Total Knee Replacement 20%
• Multiple Arms 20%
• Beta Distribution 20%
• Acceptability Threshold 20%
• Risk Acceptance 20%

Medicine and Dentistry

• Thrombosis 100%
• Risk Benefit Analysis 100%
• Ximelagatran 100%
• Orthopedic Surgery 66%
• Major Bleeding 33%
• Arm 33%
• Meta-Analysis 33%
• Placebo 33%
• Case Fatality Rate 33%
• Heparin 33%
• Clinical Decision Making 33%
• Risk-Benefit Ratio 33%
• Cost-Effectiveness Analysis 33%
• Total Knee Arthroplasty 33%
• Warfarin 33%
• Hip Replacement 33%
• Anticoagulant 33%
• Low Molecular Weight Heparin 33%
• Thromboprophylaxis 33%
• Fondaparinux 33%
• Monte Carlo Method 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Thrombosis 100%
• Ximelagatran 100%
• Anticoagulant Agent 33%
• Bleeding 33%
• Warfarin 33%
• Placebo 33%
• Case Fatality Rate 33%
• Heparin 33%
• Low Molecular Weight Heparin 33%
• Fondaparinux 33%